SCHEMBL406627

SCHEMBL406627

O=COCN(COC=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)CN(COC=O)[C@@H]1CCCC[C@H]1N(CC(=O)O)CC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.36
KCNH2 Q12809 1/20 0.36
SIGMAR1 Q99720 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 5/20 0.34
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
MAOB P27338 1/20 0.32
KMT2A Q03164 2/20 0.32
CCR5 P51681 2/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405661 1.00 EPHX1 (0.36) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL25936685 0.85 SIGMAR1 (0.41) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL14629009 0.85 SIGMAR1 (0.41) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL463616 0.85 SIGMAR1 (0.41) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL14621087 0.85 SIGMAR1 (0.41) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL463655 0.85 SIGMAR1 (0.41) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL14598858 0.85 SIGMAR1 (0.41) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL12793731 0.80 KCNH2 (0.43) KCNH2SMN1; SMN2ALDH1A1MAOBKMT2A
SCHEMBL6562226 0.77 KCNH2 (0.38) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1
SCHEMBL6561474 0.75 KCNH2 (0.38) EPHX1KCNH2SIGMAR1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064002-A1 Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents LEHMANN LUTZ (DE) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064002-A1 Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents CYP4B1, CYP2B6, UGT2B7 EPHX1 1790/4885KCNH2 2726/4885SIGMAR1 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.